FDA Questions Data Supporting ReGen's Menaflex Ahead Of 510(k) Re-Review
This article was originally published in The Gray Sheet
Executive Summary
FDA raised concerns about the preclinical and clinical data used to support 510(k) clearance of ReGen Biologic's Menaflex knee repair device ahead of an unprecedented March 23 advisory panel to reconsider FDA's original clearance decision
You may also be interested in...
With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks
FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week
With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks
FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week
ReGen Challenges FDA Report's Facts And Motivation
The details of FDA's recent review of ReGen Biologics' Menaflex knee repair device clearance stunned many device industry insiders - but none so much as the company itself